Weight Loss Drug Led to Lower BMI in Teens with Obesity, Study Finds

Weight Loss Drug Led to Lower BMI in Teens with Obesity, Study Finds

Weight Loss Drug Led to Decrease BMI in Teenagers with Weight problems, Examine Finds

Semaglutide – the drug in blockbuster anti-obesity drug Wegovy – together with a way of life intervention led to a “substantial discount” within the physique mass index of overweight adolescents after greater than a yr of weekly remedies, researchers reported Wednesday within the New England Journal of Drugs.

Wegovy is presently obtainable by prescription just for adults in america. The brand new examine checked out whether or not it may well work in youngsters.

“Boy, does this occur,” stated NBC Information medical contributor Dr. Natalie Azar.

The examine concerned 201 overweight individuals in america and different international locations between the ages of 12 and 17 and had been randomly assigned to obtain both a weekly injection of semaglutide or a placebo. The dose of the drug was the identical because the dose authorized for adults.

Each teams additionally obtained a way of life intervention consisting of diet and bodily exercise counseling for weight reduction earlier than and in the course of the examine.

After 16 months of this routine, teenagers within the semaglutide group misplaced a median of practically 15 % of their physique weight, or about 34 kilos, whereas youngsters within the management group gained about 5 kilos.

“Not solely did they reduce weight, that they had an enchancment of their waistline, that they had an enchancment in ldl cholesterol,” Azar stated. It was additionally one of many first research to look at how adolescents’ high quality of life improved as they misplaced weight, “and it improved dramatically,” she famous. . “Having that further weight can have a big affect on their social growth.”

The analysis was funded by Novo Nordisk, the pharmaceutical big that makes Wegovy.

Emmalea Zummo, a 17-year-old from Jeannette, Pennsylvania, was one of many teenagers enrolled within the examine who obtained semaglutide. She weighed 250 kilos in the beginning, weight achieve linked to polycystic ovary syndrome, and misplaced greater than 70 kilos in the course of the trial.

Emmalea Zummo (Courtesy of Emmalea Zummo)

“I felt higher about myself than I had ever felt earlier than,” she instructed NBC Information.

The protection profile of semaglutide in overweight adolescents within the trial was in line with that seen in adults, the researchers wrote. The drug “doesn’t seem to have an effect on pubertal development or growth,” they famous.

“There aren’t any developmental points, however with any drug there are negative effects. The primary negative effects of this class of medication are GI (gastrointestinal) – nausea, vomiting, diarrhea,” stated at present Dr. Silva Arslanian, scientific director of the Middle for Pediatric Weight problems and Metabolism Analysis at Youngsters’s Hospital of Pittsburgh, is a co-author of the examine.

“None of our individuals had disrupted college work. However after all it is extremely particular person.

Nearly two-thirds of youngsters taking semaglutide, 62%, skilled gastrointestinal negative effects, in comparison with 42% of youngsters taking a placebo.

Semaglutide belongs to a category of medication referred to as GLP-1 receptor agonists and works by mimicking a pure hormone that the physique releases when an individual eats meals. This hormone targets areas of the mind that regulate urge for food and meals consumption. Researchers consider its motion within the mind helps folks really feel full sooner, in order that they eat lower than normal.

It really works higher for weight reduction in overweight adolescents than the approach to life intervention alone for a number of causes, together with the truth that starvation and satiety are pushed by the central nervous system, Arslanian stated.

Moreover, “we dwell in an obesogenic setting the place wholesome life-style selections should not really easy to implement…(and) wholesome each day bodily exercise has been changed by non-screen-burning actions. energy,” she famous.

The youngsters had no issue injecting the drug, “but when you understand or have youngsters, mother and father often want to look at or remind them of no matter life duties they’re doing,” stated famous Arslanian.

The drug prices about $1,300 a month, and medical health insurance typically does not cowl weight problems medicine. Sufferers should preserve taking it for it to work, in any other case they might regain the burden they misplaced.

Requested if there have been any issues about younger sufferers beginning this drug so early in life and taking it indefinitely, Arslanian stated: “It is a actually good query that is on the radar. from everybody. I’m certain that with new scientific advances, we can discover a answer.

Semaglutide has been within the information rather a lot currently. Additionally it is the lively ingredient in Ozempic, a prescription drug to deal with sort 2 diabetes and Wegovy’s sister drug. Ozempic has not been authorized for weight reduction, however many individuals who do not have diabetes use it off-label – the observe of taking an authorized drug for unapproved use – and credit score it with their success. weightloss.

Demand for each medicine impacts provide. The US Meals and Drug Administration lists Wegovy and Ozempic as “presently in brief provide” on its web site.

Novo Nordisk is experiencing provide shortages from Wegovy resulting from “unprecedented product demand and near-term manufacturing points,” the corporate famous on its web site. He requested docs to droop therapy of latest sufferers with the drug for now, however stated he was on observe to make all doses obtainable in america by the top of this yr.

FDA approval for utilizing semaglutide for weight reduction in overweight teenagers might are available 2023, Azar stated.

This text initially appeared on


Back to list

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *